Trial Profile
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Safety and Efficacy of Tisagenlecleucel in Pediatric Subjects With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma (NHL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Tisagenlecleucel (Primary) ; Tocilizumab (Primary)
- Indications B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms BIANCA
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 23 May 2023 This trial has been completed in Netherlands, according to European Clinical Trials Database record.
- 10 May 2023 Status changed from active, no longer recruiting to completed.
- 27 Apr 2023 This trial has been completed in France, according to European Clinical Trials Database record.